News|Articles|September 1, 2026

5 Psychiatry Headlines You Missed in August 2026

Fact checked by: Tim Smith

A regulatory resubmission, 2 phase 3 psychedelic trial readouts, new TMS dosing data, and an MDD genetics study, all in this August 2026 recap.

August brought fresh movement in psychiatry's psychedelic pipeline, with a resubmission of the new drug application (NDA) for MDMA-assisted therapy and phase 3 data on lysergide for anxiety. TMS practice also saw new data this month, from a look back at how far session times have shrunk to fresh questions about whether current dosing conventions are even the right ones.

Related to this article

October 16th, 2026

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

George Washko, MD, discusses a late-breaking OBERON/TITANIA analysis showing tozorakimab reduces segmental mucus plug scores in COPD.

October 16th, 2026

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

Advanced practice providers described how documentation, specialty pharmacy support, and payer requirements shape biologic selection and timing.

October 16th, 2026

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Participants said payer criteria and patient goals often outweigh mechanism when choosing biologics, and that shared decision-making is harder in COPD.

Adrian Dan, MD | Image Credit: Summa Health

October 16th, 2026

Revita Reduces Weight Regain After GLP-1 Discontinuation in REMAIN-1

A single Revita procedure preserved about 80% of tirzepatide-induced weight loss at six months in the REMAIN-1 pivotal cohort.

October 16th, 2026

Diabetes Dialogue: Twiist AID Data and the New ADA/EASD Type 2 Algorithm

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a major breakthrough with the Twiist insulin pump and the recent ADA/EASD T2D guidelines.

October 16th, 2026

AASLD Expert Opinion Updates Liver Biopsy Guidance

AASLD’s first Expert Practice Opinion adds EUS-guided biopsy and sets no INR or platelet thresholds.

October 16th, 2026

Elafibranor Lowers ALP in PBC Patients Switching From Obeticholic Acid

Real-world data from ACG 2026 show elafibranor lowered ALP in patients with PBC who switched from obeticholic acid and in those new to second-line therapy.

October 15th, 2026

Q&A: Nemolizumab Sustains Itch, Skin Gains in Early Responders at 3 Years

Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.